Zhengye Biotechnology Holding Limited logo

Zhengye Biotechnology (ZYBT) stock

ZYBT · Zhengye Biotechnology Holding Limited · NASDAQ

Market cap
$72.0M
Shares out
47.4M

What is the latest news on ZYBT stock?

PRago
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

JILIN, China, Nov. 12, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its unaudited financial results for the six months ended June 30, 2026. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "During the first half of fiscal year 2026, we continued to enhance profitability through disciplined cost management and operational efficiency. Despite the decline in net revenue and gross profit, we are encouraged by the improvement in our gross pr

All ZYBT news

Financial highlights

Full financials
Revenue, FY2025
CN¥116.36M
Revenue growth
-37.6%
Net income, FY2025
-CN¥69.78M
Net margin
-60.0%
Free cash flow, FY2025
CN¥12.32M
Cash
CN¥50.33M

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

Latest news

25 items
News · 26 weeks13+100%
2026-05-24: 02026-05-31: 22026-06-07: 02026-06-14: 02026-06-21: 52026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 22026-07-26: 02026-08-02: 22026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 02026-11-08: 22026-11-15: 0
2026-05-242026-11-15
Mix290d
  • SEC Filings1(50%)
  • Offering1(50%)
Activity · 52 weeks2512 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Zhengye Biotechnology Holding Limited (ZYBT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for ZYBT, including 1 SEC filing and 1 offering. The most recent was published Nov 12, 2026.

ZYBT FAQ

8 questions
  • What is ZYBT revenue?
    Zhengye Biotechnology Holding Limited (ZYBT) reported CN¥116.36M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 37.6% from the year before.
  • Is ZYBT profitable?
    No. Zhengye Biotechnology Holding Limited reported a net loss of CN¥69.78M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does ZYBT have?
    Zhengye Biotechnology Holding Limited reported CN¥50.33M in cash and cash equivalents and CN¥9.55M of debt on its most recent balance sheet in SEC filings.
  • Where does ZYBT stock trade?
    Zhengye Biotechnology Holding Limited (ZYBT) is listed on NASDAQ.
  • What sector and industry is ZYBT in?
    Zhengye Biotechnology Holding Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Zhengye Biotechnology Holding Limited go public?
    Zhengye Biotechnology Holding Limited (ZYBT) completed its IPO in 2025.
  • What companies are similar to ZYBT?
    Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare ZYBT side-by-side with any of them on Quantisnow.
  • How can I track ZYBT on Quantisnow?
    Quantisnow aggregates Zhengye Biotechnology Holding Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZYBT to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change